Search

Your search keyword '"Park, Sophie"' showing total 835 results
Start Over Author "Park, Sophie"
835 results on '"Park, Sophie"'

154. Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Author

Platzbecker, Uwe, primary, Kubasch, Anne Sophie, additional, Giagounidis, Aristoteles, additional, Metzgeroth, Georgia, additional, Jonasova, Anna, additional, Herbst, Regina, additional, Torregrosa Diaz, Jose Miguel, additional, De Renzis, Benoit, additional, Götze, Katharina, additional, Huetter-Kroenke, Marie-Luise, additional, Gourin, Marie-Pierre, additional, Slama, Borhane, additional, Dimicoli-Salazar, Sophie, additional, Cony-Makhoul, Pascale, additional, Laribi, Kamel, additional, Park, Sophie, additional, Jersemann, Katja, additional, Tiebel, Oliver, additional, Sockel, Katja, additional, Gloaguen, Silke, additional, Mies, Anna, additional, Chermat, Fatiha, additional, Thiede, Christian, additional, Sapena, Rosa, additional, Schlenk, Richard F., additional, Fenaux, Pierre, additional, and Ades, Lionel, additional

Published
2019
Full Text
View/download PDF

155. De novo adult acute myeloid leukemia patients’ display at diagnosis functional deregulation of redox balance correlated with molecular subtypes and overall survival

Author

Mondet, Julie, primary, Presti, Caroline Lo, additional, Garrel, Catherine, additional, Skaare, Kristina, additional, Mariette, Clara, additional, Carras, Sylvain, additional, Park, Sophie, additional, Carré, Martin, additional, Bulabois, Claude-Eric, additional, Molina, Lysiane, additional, Gressin, Rémy, additional, Thiebaut, Anne, additional, Courby, Stéphane, additional, Socoro-Yuste, Nuria, additional, Faure, Patrice, additional, Leer, Anne Mc, additional, Cahn, Jean-Yves, additional, and Mossuz, Pascal, additional

Published
2019
Full Text
View/download PDF

159. Pseudouveitis: a clue to the diagnosis of primary central nervous system lymphoma in immunocompetent patients

Author

Park, Sophie, Abad, Sebastien, Tulliez, Micheline, Monnet, Dominique, Merlat, Annabelle, Gyan, Emmanuel, Bouscary, Didier, Dreyfus, Francois, Grimaldi, David, Dhote, Robin, Rollot, Florence, Kelaidi, Charikleia, Nazal, Eve-Marie, Brezin, Antoine P., and Blanche, Philippe

Subjects
Neurological research -- Case studies, Vitrectomy -- Complications, Vitrectomy -- Methods, Lymphomas -- Risk factors, Lymphomas -- Diagnosis, Lymphomas -- Care and treatment, Lymphomas -- Research
Published
2004

160. Dyserythropoiesis Evaluated By Red Score and Hepcidin/Ferritin Levels Predicts Response to Epoetin Zeta in Lower Risk MDS

Author

Kosmider, Olivier, Maloisel, Frederic, Drenou, Bernard, Chapuis, Nicolas, Alary, Anne Sophie, Rousseau, Alice, Bouilloux, Cecile, Ducamp, Sarah, Verdier, Frederique, Lefebvre, Thibaud, Zoubida Karim, Marie-Christine Jacob, Debliquis, Agathe, Charpentier, Agnes, Fenaux, Pierre, Gyan, Emmanuel, Anglaret, Bruno, Leyronnas, Cecile, Corm, Selim, Borhane Slama, Stephane Cheze, Laribi, Kamel, Ame, Shanti, Rose, Christian, Lachenal, Florence, Toma, Andrea, Pica, Gian Matteo, Garban, Frederic, Pegourie, Brigitte, Jean-Yves Cahn, Wagner-Ballon, Orianne, Herault, Olivier, Meunier, Mathieu, Bardet, Valerie, Fontenay, Michaela, and Park, Sophie

Published
2018
Full Text
View/download PDF

164. Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate

Author

Zannoni, Johanna, primary, Mauz, Natacha, additional, Seyve, Landry, additional, Meunier, Mathieu, additional, Pernet-Gallay, Karin, additional, Brault, Julie, additional, Jouzier, Claire, additional, Laurin, David, additional, Pezet, Mylène, additional, Pernollet, Martine, additional, Cahn, Jean-Yves, additional, Cognasse, Fabrice, additional, Polack, Benoît, additional, and Park, Sophie, additional

Published
2019
Full Text
View/download PDF

167. Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes: a diagnostic accuracy study

Author

Raskovalova, Tatiana, primary, Berger, Marc G., additional, Jacob, Marie-Christine, additional, Park, Sophie, additional, Campos, Lydia, additional, Aanei, Carmen Mariana, additional, Kasprzak, Julie, additional, Pereira, Bruno, additional, Labarère, José, additional, Cesbron, Jean-Yves, additional, and Veyrat-Masson, Richard, additional

Published
2019
Full Text
View/download PDF

168. Adult patients with de novo acute myeloid leukemia show a functional deregulation of redox balance at diagnosis which is correlated with molecular subtypes and overall survival

Author

Mondet, Julie, primary, Presti, Caroline Lo, additional, Garrel, Catherine, additional, Skaare, Kristina, additional, Mariette, Clara, additional, Carras, Sylvain, additional, Park, Sophie, additional, Carré, Martin, additional, Bulabois, Claude-Eric, additional, Molina, Lysiane, additional, Gressin, Rémy, additional, Thiebaut, Anne, additional, Courby, Stéphane, additional, Socoro-Yuste, Nuria, additional, Faure, Patrice, additional, Leer-Florin, Anne Mc, additional, Cahn, Jean-Yves, additional, and Mossuz, Pascal, additional

Published
2019
Full Text
View/download PDF

169. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

Author

Sébert, Marie, primary, Renneville, Aline, additional, Bally, Cécile, additional, Peterlin, Pierre, additional, Beyne-Rauzy, Odile, additional, Legros, Laurence, additional, Gourin, Marie-Pierre, additional, Sanhes, Laurence, additional, Wattel, Eric, additional, Gyan, Emmanuel, additional, Park, Sophie, additional, Stamatoullas, Aspasia, additional, Banos, Anne, additional, Laribi, Kamel, additional, Jueliger, Simone, additional, Bevan, Luke, additional, Chermat, Fatiha, additional, Sapena, Rosa, additional, Nibourel, Olivier, additional, Chaffaut, Cendrine, additional, Chevret, Sylvie, additional, Preudhomme, Claude, additional, Adès, Lionel, additional, and Fenaux, Pierre, additional

Published
2019
Full Text
View/download PDF

170. Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes

Author

Meunier, Mathieu, Ancelet, Sarah, Lefebvre, Christine, Arnaud, Josyane, Garrel, Catherine, Pezet, Mylène, Wang, Yan, Faure, Patrice, Szymanski, Gautier, Duployez, Nicolas, Preudhomme, Claude, Biard, Denis, Polack, Benoît, Cahn, Jean-Yves, Moulis, Jean Marc, Park, Sophie, Université du Québec à Montréal = University of Québec in Montréal (UQAM), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratory of Fundamental and Applied Bioenergetics = Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre Hospitalier Universitaire [Grenoble] (CHU), Unité de Biochimie Hormonale et Nutritionnelle, Département de Biologie - Toxicologie - Pharmacologie, Centre d'Explorations Fonctionnelles Intégré (CEFI), Institut National de la Santé et de la Recherche Médicale (INSERM), Leibniz Universität Hannover=Leibniz University Hannover, Institut de Biologie et de Pathologie (DBTP), CHU Grenoble, Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Service d'Hématologie Cellulaire [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Thérapeutique Recombinante Expérimentale (TIMC-IMAG-TheREx), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Grenoble, Leibniz Universität Hannover [Hannover] (LUH), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

173. A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial

Author

Ades, Lionel, primary, Guerci, Agnès, additional, Laribi, Kamel, additional, Peterlin, Pierre, additional, Vey, Norbert, additional, Thepot, Sylvain, additional, Wickenhauser, Stefan, additional, Zerazhi, Hacene, additional, Stamatoullas, Aspasia, additional, Wattel, Eric, additional, Recher, Christian, additional, Toma, Andrea, additional, Bouabdallah, Krimo, additional, Braun, Thorsten, additional, Beyne-Rauzy, Odile, additional, Gruson, Berengere, additional, Cheze, Stephane, additional, Park, Sophie, additional, Cluzeau, Thomas, additional, Nimubona, Stanislas, additional, Bordessoule, Dominique, additional, Benramdane, Riad, additional, Quesnel, Bruno, additional, Ame, Shanti, additional, De Botton, Stephane, additional, Chermat, Fatiha, additional, Lejeune, Julie, additional, Chevret, Sylvie, additional, and Fenaux, Pierre, additional

Published
2018
Full Text
View/download PDF

175. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes

Author

Park, Sophie, primary, Kosmider, Olivier, additional, Maloisel, Frédéric, additional, Drenou, Bernard, additional, Chapuis, Nicolas, additional, Lefebvre, Thibaud, additional, Karim, Zoubida, additional, Puy, Hervé, additional, Alary, Anne Sophie, additional, Ducamp, Sarah, additional, Verdier, Frédérique, additional, Bouilloux, Cécile, additional, Rousseau, Alice, additional, Jacob, Marie-Christine, additional, Debliquis, Agathe, additional, Charpentier, Agnes, additional, Gyan, Emmanuel, additional, Anglaret, Bruno, additional, Leyronnas, Cecile, additional, Corm, Selim, additional, Slama, Borhane, additional, Cheze, Stephane, additional, Laribi, Kamel, additional, Amé, Shanti, additional, Rose, Christian, additional, Lachenal, Florence, additional, Toma, Andrea, additional, Pica, Gian Matteo, additional, Carre, Martin, additional, Garban, Frédéric, additional, Mariette, Clara, additional, Cahn, Jean-Yves, additional, Meunier, Mathieu, additional, Herault, Olivier, additional, Fenaux, Pierre, additional, Wagner-Ballon, Orianne, additional, Bardet, Valerie, additional, Dreyfus, Francois, additional, and Fontenay, Michaela, additional

Published
2018
Full Text
View/download PDF

177. Lost in reviews: Looking for the involvement of stakeholders, patients, public and other non‐researcher contributors in realist reviews.

Author

Abrams, Ruth, Park, Sophie, Wong, Geoff, Rastogi, Juhi, Boylan, Anne‐Marie, Tierney, Stephanie, Petrova, Mila, Dawson, Shoba, and Roberts, Nia

Subjects
*MEDICAL personnel, *TEXT files, *PATIENTS, *NATURE, *MEDICAL care
Abstract

The involvement of non‐researcher contributors (eg, stakeholders, patients and the public, decision and policy makers, experts, lay contributors) has taken a variety of forms within evidence syntheses. Realist reviews are a form of evidence synthesis that involves non‐researcher contributors yet this practice has received little attention. In particular, the role of patient and public involvement (PPI) has not been clearly documented. This review of reviews describes the ways in which contributor involvement, including PPI, is documented within healthcare realist reviews published over the last five years. A total of 448 papers published between 2014 and 2019 were screened, yielding 71 full‐text papers included in this review. Statements about contributor involvement were synthesized across each review using framework analysis. Three themes are described in this article including nomenclature, nature of involvement, and reporting impact. Papers indicate that contributor involvement in realist reviews refers to stakeholders, experts, or advisory groups (ie, professionals, clinicians, or academics). Patients and the public are occasionally subsumed into these groups and in doing so, the nature and impact of their involvement become challenging to identify and at times, is lost completely. Our review findings indicate a need for the realist review community to develop guidance to support researchers in their future collaboration with contributors, including patients and the public. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

178. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis

Author

Beyne-Rauzy, Odile, Sebert, Marie, Sapena, Rosa, Zerazhi, Hacène, Legros, Laurence, Guerci-Bresler, Agnès, Ame, Shanti Natarjan, Germing, Ulrich, Santini, Valeria, Salvi, Flavia, Gioia, Daniela, Lunghi, Monia, Dreyfus, François, Fenaux, Pierre, Sindromi, Fdn Italiana, Registry, Dusseldorf Mds, Gyan, Emmanuel, Andrieu, Valerie, Sanna, Alessandro, Caille, Agnès, Schemenau, Jennifer, Sudaka, Isabelle, Siguret, Virginie, Malet, Michele, Park, Sophie, Bordessoule, Dominique, Mairesse, Jacques, Gelsi-Boyer, Véronique, Cheze, Stephane, Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Médecine Interne Onco-hématologie, Centre Hospitalier Général, Service d'Hématologie Clinique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Department of Haematology, Oncology and Clinical Immunology, Centre for Haematology and Oncology, Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Service d'hématologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hémopathies Myéloïdes : Cellules Souches, Modèles Pré-Cliniques et Recherche Translationnelle (UMR 1131), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d’Hématologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CIC - Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Thrombose : Épidémiologie, Physiopathologie et Thérapeutiques Innovantes (UMR_S 765), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Économie et Statistique (CREST), Ecole Nationale de la Statistique et de l'Analyse de l'Information [Bruz] (ENSAI)-École polytechnique (X)-École Nationale de la Statistique et de l'Administration Économique (ENSAE Paris)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Interne et Immunopathologie, CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Heinrich-Heine-Universität Düsseldorf [Düsseldorf], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Hémopathies Myéloïdes : Cellules Souches, Modèles Pré-Cliniques et Recherche Translationnelle, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], IUH- Institut Universitaire d'hématologie, Université Paris Diderot - Paris 7 ( UPD7 ), CHRU Tours, CHRU Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), CIC 1415, Institut National de la Santé et de la Recherche Médicale-Université Francois Rabelais [Tours], Thrombose : Épidémiologie, Physiopathologie et Thérapeutiques Innovantes ( UMR_S 765 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Cochin [AP-HP], Contrôle de la Réponse Immune B et des Lymphoproliférations ( CRIBL ), Université de Limoges ( UNILIM ) -Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Recherche en Économie et Statistique ( CREST ), Ecole Nationale de la Statistique et de l'Analyse de l'Information [Bruz] ( ENSAI ) -École polytechnique ( X ) -École Nationale de la Statistique et de l'Administration Économique ( ENSAE ParisTech ), Centre de Recherche en Cancérologie de Marseille ( CRCM ), Aix Marseille Université ( AMU ) -Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Francois Rabelais [Tours], Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Ecole Nationale de la Statistique et de l'Analyse de l'Information [Bruz] (ENSAI)-École polytechnique (X)-École Nationale de la Statistique et de l'Administration Économique (ENSAE ParisTech )-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Pediatrics, medicine.medical_specialty, classifications, diagnostic haematology, MDS, neutropenia, thrombocytopenia, Hematology, business.industry, Myelodysplastic syndromes, Neutropenia, medicine.disease, World health, 3. Good health, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 03 medical and health sciences, 0302 clinical medicine, Refractory, Dysplasia, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 030220 oncology & carcinogenesis, Immunology, medicine, Young adult, business, ComputingMilieux_MISCELLANEOUS, 030215 immunology
Abstract

International audience; no abstract

Published
2016

179. Faire vivre et grandir une communauté de chefs de service : Acte 2 en hématologie

Author

Houot, Roch, Calmettes, Claire, Park, Sophie, Pascal, Laurent, Peffault de Latour, Regis, Pigneux, Arnaud, Quinquenel, Anne, Raffoux, Emmanuel, Thieblemont, Catherine, Touati, Mohamed, Trebouet, Adrien, Vaida, Ioana, Wémeau, Mathieu, Bastie, Jean-Noël, Bay, Jacques-Olivier, Cluzeau, Thomas, Cornillon, Jérôme, Damaj, Ghandi, Deconinck, Eric, Feugier, Pierre, Fornecker, Luc-Matthieu, Gay, Julie, Hermine, Olivier, Hospital, Marie Anne, Hunault, Mathilde, Jaccard, Arnaud, Jardin, Fabrice, Calloch, Ronan Le, Legros, Laurence, Leleu, Xavier, Lemonnier, François, Malfuson, Jean-Valere, Morel, Pierre, Ochmann, Marlene, Orsini-Piocelle, Frédérique, and Gyan, Emmanuel

Abstract

Face à la crise de notre système hospitalier et aux défis que rencontrent les chefs de service, nous avons entrepris de créer une communauté de chefs de service d’hématologie prêts à s’entraider. Un premier séminaire a eu lieu en janvier 2023 : celui-ci a regroupé une quinzaine de chefs de service et permis de créer le premier « noyau » de la communauté. Cette communauté naissante a ensuite continué de vivre et de s’entraider tout au long de l’année 2023. En janvier 2024, nous avons élargi notre communauté à d’autres chefs de service à l’occasion d’un deuxième séminaire qui a réuni 36 participants. Au cours de cette rencontre, nous avons pris le temps de réfléchir et d’échanger ensemble sur nos missions. Nous nous sommes appuyés sur des intervenants extérieurs ainsi que sur des méthodes de co-développement et de co-construction au cours de sessions plénières, d’ateliers en petits groupes, et de temps de convivialité. Nous avons ainsi pu découvrir et expérimenter le pouvoir de l’intelligence collective, la créativité, la force, et le soutien émanant d’un tel groupe. Cette communauté de pairs, constituée de chefs de service, se révèle être un puissant outil de soutien au management. L’expérience des uns nourrit et enrichit celle des autres. Nous espérons que notre initiative inspirera des chefs de service d’autres spécialités afin qu’ensemble nous puissions mieux répondre à nos missions de chefs de service et participer à la reconstruction de l’hôpital « à partir du terrain ».

Published
2024
Full Text
View/download PDF

180. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia

Author

Fraison, Jean-Baptiste, Mekinian, Arsène, Grignano, Eric, Kahn, Jean-Emmanuel, Arlet, Jean-Benoit, Decaux, Olivier, Denis, Guillaume, Buchdahl, Anne-Laure, Omouri, Mohamed, Maigne, Gwenola, Aouba, Achille, Leon, Nathalie, Berthier, Sabine, Liozon, Eric, Park, Sophie, Gardin, Claude, Lortholary, Olivier, Rossignol, Julien, Fenaux, Pierre, Fain, Olivier, and Braun, Thorsten

Published
2016
Full Text
View/download PDF

182. Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies

Author

Drevon, Louis, primary, Marceau, Alice, additional, Maarek, Odile, additional, Cuccuini, Wendy, additional, Clappier, Emmanuelle, additional, Eclache, Virginie, additional, Cluzeau, Thomas, additional, Richez, Valentine, additional, Berkaoui, Inès, additional, Dimicoli‐Salazar, Sophie, additional, Bidet, Audrey, additional, Vial, Jean‐Philippe, additional, Park, Sophie, additional, Vieira Dos Santos, Christina, additional, Kaphan, Eléonore, additional, Berthon, Céline, additional, Stamatoullas, Aspasia, additional, Delhommeau, François, additional, Abermil, Nassera, additional, Braun, Thorsten, additional, Sapena, Rosa, additional, Lusina, Daniel, additional, Renneville, Aline, additional, Adès, Lionel, additional, Raynaud, Sophie, additional, and Fenaux, Pierre, additional

Published
2018
Full Text
View/download PDF

184. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

Author

Díez-Campelo, María, primary, Lorenzo, Jose I., additional, Itzykson, Raphael, additional, Rojas, Silvia M., additional, Berthon, Céline, additional, Luño, Elisa, additional, Beyne-Rauzy, Odile, additional, Perez-Oteyza, Jaime, additional, Vey, Norbert, additional, Bargay, Joan, additional, Park, Sophie, additional, Cedena, Teresa, additional, Bordessoule, Dominique, additional, Muñoz, Juan A., additional, Gyan, Emmanuel, additional, Such, Esperanza, additional, Visanica, Sorin, additional, López-Cadenas, Félix, additional, de Botton, Stéphane, additional, Hernández-Rivas, Jesús M., additional, Ame, Shanti, additional, Stamatoullas, Aspasia, additional, Delaunay, Jacques, additional, Salanoubat, Celia, additional, Isnard, Françoise, additional, Guieze, Romain, additional, Pérez Guallar, Joan, additional, Badiella, Llorenc, additional, Sanz, Guillermo, additional, Cañizo, Consuelo, additional, and Fenaux, Pierre, additional

Published
2018
Full Text
View/download PDF

187. Dyserythropoiesis Evaluated by Red Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes

Author

Park, Sophie, primary, Kosmider, Olivier, additional, Maloisel, Frederic, additional, Drenou, Bernard, additional, Chapuis, Nicolas, additional, Lefebvre, Thibaud, additional, Karim, Zoubida, additional, Puy, Hervé, additional, Alary, Anne Sophie, additional, Rousseau, Alice, additional, Bouilloux, Cecile, additional, Ducamp, Sarah, additional, Verdier, Frederique, additional, Jacob, Marie-Christine, additional, Debliquis, Agathe, additional, Charpentier, Agnes, additional, Gyan, Emmanuel, additional, Anglaret, Bruno, additional, Leyronnas, Cecile, additional, Corm, Selim, additional, Slama, Borhane, additional, Cheze, Stephane, additional, Laribi, Kamel, additional, Amé, Shanti, additional, Rose, Christian, additional, Lachenal, Florence, additional, Toma, Andrea, additional, Pica, Gian Matteo, additional, Carre, Martin, additional, Garban, Frederic, additional, Mariette, Clara, additional, Cahn, Jean-Yves, additional, Meunier, Mathieu, additional, Herault, Olivier, additional, Fenaux, Pierre, additional, Wagner-Ballon, Orianne, additional, Bardet, Valerie, additional, Fontenay, Michaela, additional, and Dreyfus, Francois, additional

Published
2018
Full Text
View/download PDF

188. Red Blood Cell Transfusion Burden in Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS): A Retrospective Multicenter Study By the Groupe Francophone Des Myélodysplasies (GFM)

Author

Jouzier, Claire, Cherait, Amina, Cony-Makhoul, Pascale, Thepot, Sylvain, Cluzeau, Thomas, Stamatoulas Bastard, Aspasia, Peterlin, Pierre, Guerci Bresler, Agnes, Dimicoli-Salazar, Sophie, Pica, Gian-Matteo, Cheze, Stephane, Santana, Clémence, Chermat, Fatiha, Fenaux, Pierre, and Park, Sophie

Published
2020
Full Text
View/download PDF

189. Exploring provision of Innovative Community Education Placements (ICEPs) for junior doctors in training: a qualitative study

Author

Griffin, Ann, Jones, Melvyn M, Khan, Nada, Park, Sophie, Rosenthal, Joe, and Chrysikou, Vasiliki

Subjects
Attitude of Health Personnel, Research, Teaching, Mentors, education, Medical Education and Training, Interviews as Topic, MEDICAL EDUCATION & TRAINING, PRIMARY CARE, England, Medical Staff, Hospital, Humans, Community Health Services, SOCIAL MEDICINE, Qualitative Research, Education, Medical, Undergraduate
Abstract

OBJECTIVE: Medical education in community settings is an essential ingredient of doctors' training and a key factor in recruiting general practitioners (GP). Health Education England's report 'Broadening the Foundation' recommends foundation doctors complete 4-month community placements. While Foundation GP schemes exist; other community settings, are not yet used for postgraduate training. The objective of this study was to explore how community-based training of junior doctors might be expanded into possible 'innovative community education placements' (ICEPs), examining opportunities and barriers to these developments. DESIGN: A qualitative study where semistructured interviews were undertaken and themes were generated deductively from the research questions, and iteratively from transcripts. SETTING: UK community healthcare. PARTICIPANTS: Stakeholders from UK Community healthcare providers and undergraduate GP and community educators. RESULTS: Nine participants were interviewed; those experienced in delivering community-based undergraduate education, and others working in community settings that had not previously trained doctors. Themes identified were practicalities such as 'finance and governance', 'communication and interaction', 'delivery of training' and 'perceptions of community'. ICEPs were willing to train Foundation doctors. However, concerns were raised that large numbers and inadequate resources could undermine the quality of educational opportunities, and even cause reputational damage. Organisation was seen as a challenge, which might be best met by placing some responsibility with trainees to manage their placements. ICEP providers agreed that defined service contribution by trainees was required to make placements sustainable, and enhance learning. ICEPs stated the need for positive articulation of the learning value of placements to learners and stakeholders. CONCLUSIONS: This study highlighted the opportunities for foundation doctors to gain specialist and generalist knowledge in ICEPs from diverse clinical teams and patients. We recommend in conclusion ways of dealing with some of the perceived barriers to training.

Published
2016

191. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy

Author

Prebet, Thomas, primary, Cluzeau, Thomas, additional, Park, Sophie, additional, Sekeres, Mikkael A., additional, Germing, Ulrich, additional, Ades, Lionel, additional, Platzbecker, Uwe, additional, Gotze, Katharina, additional, Vey, Norbert, additional, Oliva, Esther, additional, Sugrue, Mary M., additional, Bally, Cecile, additional, Kelaidi, Charikleia, additional, Al Ali, Najla, additional, Fenaux, Pierre, additional, Gore, Steven D., additional, and Komrokji, Rami, additional

Published
2017
Full Text
View/download PDF

192. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

Author

Park, Sophie, primary, Hamel, Jean-François, additional, Toma, Andrea, additional, Kelaidi, Charikleia, additional, Thépot, Sylvain, additional, Campelo, Maria Diez, additional, Santini, Valeria, additional, Sekeres, Mikkael A., additional, Balleari, Enrico, additional, Kaivers, Jennifer, additional, Sapena, Rosa, additional, Götze, Katharina, additional, Müller-Thomas, Catharina, additional, Beyne-Rauzy, Odile, additional, Stamatoullas, Aspasia, additional, Kotsianidis, Ioannis, additional, Komrokji, Rami, additional, Steensma, David P., additional, Fensterl, Jaime, additional, Roboz, Gail J., additional, Bernal, Teresa, additional, Ramos, Fernando, additional, Calabuig, Marisa, additional, Guerci-Bresler, Agnès, additional, Bordessoule, Dominique, additional, Cony-Makhoul, Pascale, additional, Cheze, Stéphane, additional, Wattel, Eric, additional, Rose, Christian, additional, Vey, Norbert, additional, Gioia, Daniela, additional, Ferrero, Dario, additional, Gaidano, Gianluca, additional, Cametti, Giovanni, additional, Pane, Fabrizio, additional, Sanna, Alessandro, additional, Germing, Ulrich, additional, Sanz, Guillermo F., additional, Dreyfus, François, additional, and Fenaux, Pierre, additional

Published
2017
Full Text
View/download PDF

196. Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Author

Sebert, Marie, primary, Bally, Cecile, additional, Peterlin, Pierre, additional, Beyne-Rauzy, Odile, additional, Legros, Laurence, additional, Gourin, marie Pierre, additional, Sanhes, Laurence, additional, Wattel, Eric, additional, Gyan, Emmanuel, additional, Park, Sophie, additional, Stamatoullas, Aspasia, additional, Banos, Anne, additional, Laribi, Kamel, additional, Jueliger, Simone, additional, Bevan, Luke, additional, Chaffaut, Cendrine, additional, Sapena, Rosa, additional, Samey, Benedicte, additional, Chermat, Fatiha, additional, Chevret, Sylvie, additional, Ades, Lionel, additional, and Fenaux, Pierre, additional

Published
2016
Full Text
View/download PDF

197. Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Author

Langemeijer, Saskia, primary, De Swart, Louise, additional, Yu, Ge, additional, Smith, Alex, additional, Crouch, Simon, additional, Johnston, Tom, additional, Fenaux, Pierre, additional, Symeonidis, Argiris, additional, Cermak, Jaroslav, additional, Hellstrom-Lindberg, Eva, additional, Sanz, Guillermo, additional, Stauder, Reinhard, additional, Malcovati, Luca, additional, Germing, Ulrich, additional, Skov Holm, Mette, additional, Mittelman, Moshe, additional, Madry, Krzysztof, additional, Tatic, Aurelia, additional, Almeida, Antonio, additional, Savic, Aleksandar, additional, Park, Sophie, additional, Beyne-Rauzy, Odile, additional, Itzykson, Raphaël, additional, van Marrewijk, Corine, additional, Bowen, David, additional, and de Witte, Theo, additional

Published
2016
Full Text
View/download PDF

198. Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases

Author

Attias, Philippe, primary, Renneville, Aline, additional, Thomas, Xavier, additional, Bally, Cecile, additional, Hayette, Sandrine, additional, Farhat, Hassan, additional, Eclache, Virginie, additional, Marceau, Alice, additional, Cassinat, Bruno, additional, Feuillard, Jean, additional, Terré, Christine, additional, Delabesse, Eric, additional, Park, Sophie, additional, Lejeune, Julie, additional, Chevret, Sylvie, additional, Ades, Lionel, additional, Preudhomme, Claude, additional, and Fenaux, Pierre, additional

Published
2016
Full Text
View/download PDF

199. Caring for quality of care: symbolic violence and the bureaucracies of audit

Author

Emmerich, Nathan, Swinglehurst, Deborah, Maybin, Jo, Park, Sophie, Quilligan, Sally, and Apollo - University of Cambridge Repository

Subjects
Symbolism, Issues, ethics and legal aspects, Health Policy, Humans, Empathy, Violence, Morals, Delivery of Health Care, United Kingdom, Health(social science), Quality of Health Care
Abstract

BACKGROUND: This article considers the moral notion of care in the context of Quality of Care discourses. Whilst care has clear normative implications for the delivery of health care it is less clear how Quality of Care, something that is centrally involved in the governance of UK health care, relates to practice. DISCUSSION: This paper presents a social and ethical analysis of Quality of Care in the light of the moral notion of care and Bourdieu's conception of symbolic violence. We argue that Quality of Care bureaucracies show significant potential for symbolic violence or the domination of practice and health care professionals. This generates problematic, and unintended, consequences that can displace the goals of practice. SUMMARY: Quality of Care bureaucracies may have unintended consequences for the practice of health care. Consistent with feminist conceptions of care, Quality of Care 'audits' should be reconfigured so as to offer a more nuanced and responsive form of evaluation.

Published
2015

200. Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review.

Author

Park, Sophie, Greenberg, Peter, Yucel, Aylin, Farmer, Caroline, O'Neill, Frank, De Oliveira Brandao, Cisio, and Fenaux, Pierre

Subjects
*MYELODYSPLASTIC syndromes, *MEDICAL care, *ERYTHROPOIETIN, *HORMONES, *BONE marrow diseases
Abstract

Summary: Many patients with lower‐risk myelodysplastic syndrome (MDS) experience anaemia, which has negative consequences. Erythropoiesis‐stimulating agents (ESAs) and their biosimilars are used to treat anaemia in MDS and, currently, epoetin alfa and darbepoetin alfa are commonly used and recommended by clinical guidelines. To better understand the evidence available on the use of ESAs for anaemia in lower‐risk MDS, we conducted a systematic literature review to identify randomized and nonrandomized prospective studies reporting on clinical efficacy/effectiveness, patient‐reported quality of life (QoL), and safety. We extended our review to include retrospective studies for darbepoetin alfa specifically and to ascertain the feasibility of completing an indirect network meta‐analysis comparing epoetin and darbepoetin alfa. Overall, 53 articles reporting on 35 studies were included. The studies indicated a clinical benefit of ESAs, with benefits observed across key clinical outcomes. ESAs showed consistent improvement in erythroid response rates (ESA‐naïve, 45–73%; previous ESA exposure, 25–75%) and duration of response. Comparative studies demonstrated similar progression to acute myeloid leukaemia and several showed improved overall survival and QoL. Limited safety concerns were identified. This analysis confirmed ESA therapy should be the foremost first‐line treatment of anaemia in most patients with lower‐risk MDS who lack the 5q deletion. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results